Effects of GS-3K8 and GINst15 on Acute Respiratory Illness

Chonbuk National University

Status: Completed

Conditions: Acute Respiratory Infection

Treatments: Dietary Supplement: Placebo; Dietary Supplement: GINst15; Dietary Supplement: GS-3K8

Study type: Interventional

Funder types: Other

Identifiers

NCT03028077

CTCF2_2014_GN

Details and patient eligibility

About

This study was conducted to investigate the effects of daily supplementation of GS-3K8 or GINst15 on acute respiratory illness (ARI) in healthy subjects.

Full description

This study was a 8 weeks, randomized, double-blind, placebo-controlled trial. Forty five subjects were randomly divided into GS-3K8 (Ultrafiltered red ginseng extract) or GINst15 (Hydrolyzed ginseng extract) or placebo group. The primary clinical outcome measure was the incidence of ARI. The secondary clinical outcome measure was the development and duration of ARI symptoms.

Enrollment: 45 patients

Sex: All

Ages: 39 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age 39-65 years with healthy adults

Exclusion criteria

• Subjects had been vaccinated against influenza in the previous 6 months
• Subjects with symptoms of upper respiratory tract infection
• Subjects with acute/chronic disease
• History of alcohol or substance abuse
• History of disease that could interfere with the test products or impede their absorption
• Subjects taking medications such as immune or upper respiratory tract infection related drug or functional foods
• Abnormal liver or kidney function tests
• Pregnant or lactating women and heavy smokers
• Being judged by the responsible physician of the local study center as unfit to participate in the study

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

45 participants in 3 patient groups, including a placebo group

GS-3K8

Experimental group

Description:

GS-3K8 (6 cap/day, 500 mg/cap) for 12 weeks

Treatment:

Dietary Supplement: GS-3K8

GINst15

Experimental group

Description:

GINst15 (6 cap/day, 500 mg/cap) for 12 weeks

Treatment:

Dietary Supplement: GINst15

Placebo

Placebo Comparator group

Description:

Placebo for 12 weeks

Treatment:

Dietary Supplement: Placebo